CLINICAL_TRIALS
trial_result
· 2017-09-01
Clinical Trial Update: Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma [Phase 2]
Summary
Phase 2 clinical trial assessing eribulin mesylate in patients with recurrent or refractory osteosarcoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Osteosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2017-09-01